Cargando…

Effects of the Oral Angiotensin II Type 2 Receptor Agonist C21 in Sugen-Hypoxia Induced Pulmonary Hypertension in Rats

Substantial evidence supports the involvement of the renin-angiotensin system in pulmonary hypertension (PH), and the angiotensin II type 2 receptor (AT(2)R) is known to exert tissue protective actions. The effect of the selective AT(2)R agonist C21 (also known as Compound 21 or buloxibutid) was eva...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tornling, Göran, Batta, Rohit, Salvail, Dan, Raud, Johan, Denton, Christopher P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10139154/ https://www.ncbi.nlm.nih.gov/pubmed/37108643 http://dx.doi.org/10.3390/ijms24087478

Ejemplares similares

A phase 2 trial investigating the effects of the angiotensin II type 2 receptor agonist C21 in systemic sclerosis-related Raynaud’s
por: Herrick, Ariane L, et al.
Publicado: (2022)

Seven days treatment with the angiotensin II type 2 receptor agonist C21 in hospitalized COVID-19 patients; a placebo-controlled randomised multi-centre double-blind phase 2 trial
por: Tornling, Göran, et al.
Publicado: (2021)

Sugen, hypoxia and the lung circulation
por: Voelkel, Norbert F., et al.
Publicado: (2021)

Transpulmonary amino acid metabolism in the sugen hypoxia model of pulmonary hypertension
por: Philip, Nicolas, et al.
Publicado: (2023)

The selective PGI(2) receptor agonist selexipag ameliorates Sugen 5416/hypoxia-induced pulmonary arterial hypertension in rats
por: Honda, Yohei, et al.
Publicado: (2020)

Increased Eicosanoid Levels in the Sugen/Chronic Hypoxia Model of Severe Pulmonary Hypertension
por: Al-Husseini, Aysar, et al.
Publicado: (2015)

Spatial and temporal resolution of metabolic dysregulation in the Sugen hypoxia model of pulmonary hypertension
por: Simpson, Catherine E., et al.
Publicado: (2023)

Sugen–morphine model of pulmonary arterial hypertension
por: Agarwal, Stuti, et al.
Publicado: (2020)

Emphysema Is—at the Most—Only a Mild Phenotype in the Sugen/Hypoxia Rat Model of Pulmonary Arterial Hypertension
por: Bogaard, Harm J., et al.
Publicado: (2019)

IL‐33/ST2 receptor‐dependent signaling in the development of pulmonary hypertension in Sugen/hypoxia mice
por: Indralingam, Cynthia S., et al.
Publicado: (2022)

Direct Delivery of MicroRNA96 to the Lungs Reduces Progression of Sugen/Hypoxia-Induced Pulmonary Hypertension in the Rat
por: Docherty, Craig K., et al.
Publicado: (2020)

Using extracellular matrix derived from sugen-chronic hypoxia lung tissue to study pulmonary arterial hypertension
por: Link, Patrick A., et al.
Publicado: (2023)

MicroRNA-212-5p, an anti-proliferative miRNA, attenuates hypoxia and sugen/hypoxia-induced pulmonary hypertension in rodents
por: Chen, Tianji, et al.
Publicado: (2022)

Intratracheal Administration of Prostacyclin Analogue–incorporated Nanoparticles Ameliorates the Development of Monocrotaline and Sugen-Hypoxia-induced Pulmonary Arterial Hypertension
por: Akagi, Satoshi, et al.
Publicado: (2016)

Isolated heart model demonstrates evidence of contractile and diastolic dysfunction in right ventricles from rats with sugen/hypoxia‐induced pulmonary hypertension
por: Neto‐Neves, Evandro M., et al.
Publicado: (2017)

Reply to Bogaard et al.: Emphysema Is—at the Most—Only a Mild Phenotype in the Sugen/Hypoxia Rat Model of Pulmonary Arterial Hypertension
por: Kojonazarov, Baktybek, et al.
Publicado: (2019)

Understanding longitudinal biventricular structural and functional changes in a pulmonary hypertension Sugen–hypoxia rat model by cardiac magnetic resonance imaging
por: Jayasekera, Geeshath, et al.
Publicado: (2020)

The Adult Sprague-Dawley Sugen-Hypoxia Rat Is Still “the One:” A Model of Group 1 Pulmonary Hypertension: Reply to Le Cras and Abman
por: Bogaard, Harm J., et al.
Publicado: (2020)

Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model
por: Morales-Cano, Daniel, et al.
Publicado: (2023)

Shunt-type plexiform lesions identified in the Sugen5416/hypoxia rat model of pulmonary arterial hypertension using synchrotron-based phase-contrast micro-CT
por: van der Have, Oscar, et al.
Publicado: (2022)

Corrigendum: Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model
por: Morales-Cano, Daniel, et al.
Publicado: (2023)

Response to: Are endothelial cell proliferation and mesenchymal transition as distinguishing characteristics of 3-week Sugen5416/hypoxia mice model?
por: Rodor, Julie, et al.
Publicado: (2023)

Angiotensin II and the Cardiac Parasympathetic Nervous System in Hypertension
por: Shanks, Julia, et al.
Publicado: (2021)

Evolution of Angiotensin Peptides and Peptidomimetics as Angiotensin II Receptor Type 2 (AT2) Receptor Agonists
por: Vasile, Silvana, et al.
Publicado: (2020)

Central Infusion of Angiotensin II Type 2 Receptor Agonist Compound 21 Attenuates DOCA/NaCl-Induced Hypertension in Female Rats
por: Dai, Shu-Yan, et al.
Publicado: (2016)

Facilitation of TRKB Activation by the Angiotensin II Receptor Type-2 (AT2R) Agonist C21
por: Laukkanen, Liina, et al.
Publicado: (2021)

Two Phase II randomized trials on the CRTh2 antagonist AZD1981 in adults with asthma
por: Kuna, Piotr, et al.
Publicado: (2016)

MicroCT analysis of vascular morphometry: a comparison of right lung lobes in the SUGEN/hypoxic rat model of pulmonary arterial hypertension
por: Faight, Erin M., et al.
Publicado: (2017)

The Selective Angiotensin II Type 2 Receptor Agonist, Compound 21, Attenuates the Progression of Lung Fibrosis and Pulmonary Hypertension in an Experimental Model of Bleomycin-Induced Lung Injury
por: Rathinasabapathy, Anandharajan, et al.
Publicado: (2018)

Renal Denervation Promotes Atherosclerosis in Hypertensive Apolipoprotein E-Deficient Mice Infused with Angiotensin II
por: Wang, Yutang, et al.
Publicado: (2017)

Angiotensin II type 2 receptor agonist Compound 21 attenuates pulmonary inflammation in a model of acute lung injury
por: Menk, Mario, et al.
Publicado: (2018)

RENAL HYPERTENSION IN RATS IMMUNIZED AGAINST ANGIOTENSIN I AND ANGIOTENSIN II
por: Oates, Helen F., et al.
Publicado: (1974)

β-Arrestin–Biased Angiotensin II Receptor Agonists for COVID-19
por: Manglik, Aashish, et al.
Publicado: (2020)

Direct Angiotensin AT2 Receptor Stimulation Using a Novel AT2 Receptor Agonist, Compound 21, Evokes Neuroprotection in Conscious Hypertensive Rats
por: McCarthy, Claudia A., et al.
Publicado: (2014)

Abstract QS38: Effect of Compound 21, a Selective Angiotensin II Type 2 Receptor Agonist, in an Abdominal Adhesion Murine Model
por: Boudreau, Colton, et al.
Publicado: (2019)

Angiotensin II type 1 receptor agonistic autoantibody blockade improves postpartum hypertension and cardiac mitochondrial function in rat model of preeclampsia
por: Booz, George W., et al.
Publicado: (2021)

Pressor responsiveness to angiotensin II in female mice is enhanced with age: role of the angiotensin type 2 receptor
por: Mirabito, Katrina M, et al.
Publicado: (2014)

The Effect of a Nonpeptide Angiotensin II Type 2 Receptor Agonist, Compound 21, on Aortic Aneurysm Growth in a Mouse Model of Marfan Syndrome
por: Verbrugghe, Peter, et al.
Publicado: (2018)

Effects of compound 21, a non-peptide angiotensin II type 2 receptor agonist, on general anesthesia-induced cerebral injury in neonatal rats
por: Yong, Jun, et al.
Publicado: (2018)

Dual deficiency of angiotensin‐converting enzyme‐2 and Mas receptor enhances angiotensin II‐induced hypertension and hypertensive nephropathy
por: Ni, Jun, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_smte8a30h322ln37br8p1aa7n1